Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Sustainability & Impact
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
  • Support
    • Our Value Creation Approach
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • Investor Portal
    • JOIN OUR TEAM
    • Contact

NEWS

Our Latest News

ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.

 

 

ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.

ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising

 September

 9, 

2026

ARCHIMED Successfully Completes Take-private of Esperion Therapeutics

 July

 13, 

2026

ARCHIMED Life Science Tools & Services acquires IRAB, a leading independent radiopharmaceuticals platform

 June

 9, 

2026

ARCHIMED Healthcare IT sells global digital health solutions provider Ametris to Signant Health

 May

 28, 

2026

ARCHIMED Diagnostics acquires Stago, a global leader in blood coagulation analysis

 April

 29, 

2026

ARCHIMED Pharma Services announces the spin-off of Suanfarma’s subsidiary, SuanNutra

 December

 19, 

2025

1 2 3 … 17 >
368
  • ARCHIMED © 2026
  • Our Eco-Design Approach
  • Legal Notice
  • Contact Us
  • Videos
  • LinkedIn
  • Manage your cookies
  • .
    Go top

    Back to top